Back to Search
MICHAEL ATKINS, M.D.
M.D.
Medical Oncology Physician
NPI: 1306874201IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
MA49995(MA)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
TUFTS UNIVERSITY SCHOOL OF MEDICINE
Class of 1980
Research & Publications (20)
Treatment selection for patients with metastatic renal cell carcinoma.
PMID 19402069·Cancer·2009
6-review
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.
PMID 19402064·Cancer·2009
8-other
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy.
PMID 19165638·Med Oncol·2009
6-review
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
PMID 19001327·J Clin Oncol·2008
3-trial
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
PMID 18792064·Cancer·2008
3-trial
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
PMID 17667521·J Immunother·2007
6-review
The effect of recent drug approvals on translational research and drug development.
PMID 17607287·Clin Adv Hematol Oncol·2007
6-review
Surgical revascularization versus endovascular therapy for chronic mesenteric ischemia: a comparative experience.
PMID 17467950·J Vasc Surg·2007
4-observational
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
PMID 17255291·Clin Cancer Res·2007
6-review
Cytokine-based therapy and biochemotherapy for advanced melanoma.
PMID 16609058·Clin Cancer Res·2006
6-review
Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
PMID 16609047·Clin Cancer Res·2006
8-other
Aortic dissection: perspectives in the era of stent-graft repair.
PMID 16473168·J Vasc Surg·2006
6-review
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
PMID 15897568·Clin Cancer Res·2005
8-other
Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
PMID 15448028·Clin Cancer Res·2004
6-review
Innovations and challenges in renal cancer: consensus statement from the first international conference.
PMID 15448017·Clin Cancer Res·2004
6-review
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
PMID 14990647·J Clin Oncol·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 330 BROOKLINE AVE, KIRSTEIN 158
BOSTON, MA 02215 - Phone
- (616) 667-1930
Quick Facts
- NPI
- 1306874201
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 46
- Publications
- 20
Are you this provider?
Claim Your Profile